The Hill

Kansas sues Pfizer over ‘misleading statements’ about COVID vaccine

The state of Kansas filed a lawsuit Monday against pharmaceutical company Pfizer, alleging the company made “misleading claims” about the effectiveness of the COVID-19 vaccine and the risks associated ...
Business Wire

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union

has received another COVID-19 vaccine has ever fainted in association with an injection Side effects that have been reported with Pfizer-BioNTech COVID-19 vaccines include: Severe allergic reactions ...
Seeking Alpha

Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19

The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains 1 Shipping of the LP.8.1-adapted vaccine will ...
Nasdaq

Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine

Pfizer-BioNTech COVID-19 Vaccine is FDA authorized under Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory ...
The American Journal of Managed Care

What We’re Reading: Kaiser Permanente Data Breach; GSK Sues Pfizer, BioNTech; HIV Infections via Cosmetic Injections

Kaiser Permanente was hit by a data breach in mid-April, impacting 13.4 million health plan members; GlaxoSmithKline (GSK) sued Pfizer and BioNTech for allegedly infringing on its messenger RNA ...

Covid vaccines caused sudden deaths, FDA to put Covid – 19 under "black box" category

Our worst nightmare just came true! Scientists have established links between Covid vaccines and sudden deaths due to cardiac ...
Business Wire

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union

Upon authorization by the European Commission (EC), the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and older Data demonstrate that the Omicron KP.2-adapted ...